Australia markets closed

Amryt Pharma plc (AMYT)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
14.700.00 (0.00%)
At close: 04:00PM EDT
Full screen
Loading interactive chart…
  • PR Newswire

    Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc

    Chiesi Farmaceutici S.p.A. ("Chiesi"), an international, research-focused biopharmaceuticals and healthcare group, today announced the completion of the acquisition of Amryt Pharma Plc ("Amryt") (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases.

  • GlobeNewswire

    2022 for Chiesi: The Group’s international growth continues

    Turnover at €2 billion 749 million, with growth of 13.6% over 2021The European market remains at the center, with significant international developmentThe distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare diseases) 12% and Care (special care & consumer healthcare) 15%In 2022, Chiesi invested 21.4% of its turnover in Research & DevelopmentThe total number of employees rises to more than 6,500 people, 55% women and 45% menThe Grou

  • GlobeNewswire

    High Court of Justice of England and Wales Sanctions Scheme of Arrangement

    High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3, 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases, is pleased to announce that the High Court of Justice of England and Wales (the “Court”) has sanctioned the scheme of arra